U.S. FDA approves Bristol-Myers Squibb's multiple myeloma therapy

mediabest
FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau

(Reuters) – The U.S. Food and Drug Administration has approved Bristol-Myers Squibb Co and bluebird bio Inc’s multiple myeloma therapy, ide-cel, acquired as part of its $74 billion buyout of Celgene, the drugmakers said in a joint statement late on Friday.

Ide-cel is a CAR-T therapy that involves taking immune cells from a patient, engineering them to attack tumor cells and infusing them back into the patient.

Bristol Myers Squibb and partner bluebird bio Last year resubmitted its application for ide-cel after the U.S. drug regulator declined to review the treatment and sought more information.

As part of the Celgene-Bristol Myers deal, Celgene shareholders would have received a $9 per share payment if three of Celgene’s top pipeline assets were approved by certain dates.

However, the FDA did not approve blood cancer therapy, liso-cel, by the end of 2020 and as a result the CVR agreement was terminated. (bit.ly/3lS3Gn8)

Source: Read Full Article

Related posts:
  1. Pfizer begins early-stage study of oral COVID-19 drug
  2. U.S. government to ship 18.5 million doses of COVID vaccine this week, White House says
  3. Congo delays AstraZeneca coronavirus vaccine rollout
  4. Biden says CDC guidance on reopening schools is solid science
  5. Nigerian students design coronavirus care robot